The trithorax Group Gene moira Encodes a Brahma-Associated Putative Chromatin-Remodeling Factor in Drosophila melanogaster

MADELINE A. CROSBY,1 CHAYA MILLER,2 TAMAR ALON,2 KELLIE L. WATSON,1 C. PETER VERRIJZER,3 RONIT GOLDMAN-LEVI,2 AND NAOMI B. ZAK2*

Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138; Hubert H. Humphrey Center for Experimental Medicine and Cancer Research, Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel; and Imperial Cancer Research Fund, London WC2A 3PX, United Kingdom

Received 24 August 1998/Returned for modification 1 October 1998/Accepted 29 October 1998

The genes of the trithorax group (trxG) in Drosophila melanogaster are required to maintain the pattern of homeotic gene expression that is established early in embryogenesis by the transient expression of the segmentation genes. The precise role of each of the diverse trxG members and the functional relationships among them are not well understood. Here, we report on the isolation of the trxG gene moira (mor) and its molecular characterization. mor encodes a fruit fly homolog of the human and yeast chromatin-remodeling factors BAF170, BAF155, and SWI3. mor is widely expressed throughout development, and its 170-kDa protein product is present in many embryonic tissues. In vitro, MOR can bind to itself and it interacts with Brahma (BRM), an SWI2-SNF2 homolog, with which it is associated in embryonic nuclear extracts. The leucine zipper motif of MOR is likely to participate in self-oligomerization; the equally conserved SANT domain, for which no function is known, may be required for optimal binding to BRM. MOR thus joins BRM and Snf5-related 1 (SNR1), two known Drosophila SWI-SNF subunits that act as positive regulators of the homeotic genes. These observations provide a molecular explanation for the phenotypic and genetic relationships among several of the trxG genes by suggesting that they encode evolutionarily conserved components of a chromatin-remodeling complex.

Two classes of genes maintain regulatory decisions made during early Drosophila development by the localized expression of segmentation gene products. These are the Polycomb group (PcG) and the trithorax group (trxG) genes, which sustain, respectively, the repressed or active state of homeotic gene expression (30, 42). The trxG proteins are thought to act at many different levels of gene regulation to maintain continued and efficient expression of homeotic and other genes. While genetic tests indicate that members of this group are functionally related (see, for example, references 41 and 49), with the exception of Brahma and Snf5-related 1 (SNR1) (14), there has been no evidence that these proteins are components of the same multimeric complexes. Thus, the exact functional relationships among most members of this gene class are not yet understood.

Brahma (BRM) is a trxG protein product that is believed to increase target gene accessibility by overcoming the repressive effects of nucleosomal histones (9, 45). BRM is highly related to the Saccharomyces cerevisiae protein SNF2 (SWI2) (44), which is part of an 11-subunit, 2-MDa global regulatory complex that assists a large number of DNA-binding proteins to activate transcription of their target genes by facilitating their binding to nucleosomal sites (31, 50). Another potential fruit fly homolog of a yeast SWI-SNF component that may be involved in the regulation of homeotic gene expression is SNR1, which coisolates with BRM in a large protein complex (14). Although it was not, like most of the trxG genes, isolated in screens that were based on suppression of mutations in Polycimbus, Surl does undergo genetic interactions with classic trxG genes (14).

To unravel the functional relationships among the different trxG members and to understand how the gene products exert regulatory control over other genes, it is necessary to obtain molecular information about those members that have not yet been cloned. One such gene is moira (mor), which was isolated in three independent screens for loci that undergo dosage-dependent interactions with Polycimbus or ectopically expressed Antennapedia (29) and which exhibits many of the genetic and phenotypic characteristics of brm (6, 15, 16, 29, 44).

Here we demonstrate that mor encodes a Drosophila homolog of the S. cerevisiae SWI-SNF gene SWI3. The MOR protein sequence closely resembles those of the human SWI3-related proteins, BAF170 and BAF155 (53, 54). In accordance with its known function as a regulator of homeotic gene activity, mor is widely expressed during development and in many embryonic tissues in a spatiotemporal pattern that overlaps that of brm and Surl. MOR is capable of forming homooligomers; optimal binding of MOR to itself is likely to require its leucine zipper motif. MOR can also bind to BRM, with which it is associated in embryonic nuclear extracts; this interaction may be mediated by the SANT domain of MOR, which is common to several proteins involved in basal or activated transcription and whose function is not known (1, 54).

Identification of MOR as an additional component of the Drosophila SWI-SNF complex provides a physical and biochemical explanation for the known functional relationship between two strong and well-characterized trxG proteins, MOR and BRM. This finding provides a conceptual framework in which to continue to analyze the role of SWI-SNF proteins in...
regulation of the hemicone and other developmentally regulated genes in eukaryotic organisms.

MATERIALS AND METHODS

**Fruit fly culture and stocks.** *Drosophila melanogaster* was cultured at room temperature on standard cornmeal-yeast-extract-dextrose medium or at 18°C on Instant Medium (Carolina Biological). Except for those generated in the course of this work, all new stocks and transgenes used are described in the database FlyBase (20). *mor* region stocks and deficiencies were obtained from J. Kennison. All *mor* alleles were reevaluated over a TM3-flac au-2 balancer.

**Isolation of new allelics of *mor***. The original P(lacW) insertion mutagenesis was carried out with an attached-X amnion chromosome that carried copies of P(lacW) on each arm: C1(1)RM, y2 P(lacW)-5.45D w7 P(lacW)-4.5P P(lacW)-3.52d P(lacW)-3.76a (24). Females carrying the attached-X amnion chromosome and P(lacW)-3.52d were crossed with w; Sc and Sc; lb males. F1 males with the mini-white eye color were crossed with w; Sc and Sc; lb females. Whenever possible, homozygous insertion lines were established. F1 or F2 males were examined for changes in abdominal pigmentation or sternite bristle patterns. The insertion later designated P(lacW)-98B was mapped very close to Sc on the basis of segregation with the original Sc mutation. Mobilization of this element was accomplished by generating dysgenic males, crossing with w females, and recovering w Sc females. Of 47 w Sc chromosomes recovered, 2 were lethal over Df(3R)32B.

**Cloning of the *mor* region and molecular analysis of new excision allelics of *mor***. The P(lacW) element allows cloning of adjacent genomic sequences by plasmid rescue (56). One isolate, pCK5.128A, obtained by EcoRI digestion of flies bearing P(lacW)-98B, was labeled (random priming kit; Bethesda Research Laboratories) and used to screen a StuI3A partial genomic library of Canton-S DNA generated by using a Lambda-FIX kit (Stratagene) and high-molecular-weight genomic DNA (prepared as described in reference 34). Three independent genomic clones were recognized and characterized by restriction mapping and Southern analysis. Smaller genomic fragments were subcloned into pBlue-script II SK (Stratagene).

In the newly obtained excision mutants, *mor* and *mor*105, were subjected to Southern analysis with HindIII or EcoRI as described previously (12). As controls, the transgenesis P(lacW)-98B chromosome and a line thought to be the precise excision thereof were also analyzed. Consistent evidence of changes in both lines was obtained by using the probe CK126 (Fig. 1A). When the original blot was reprobed with pCaSpeR and p blue-script, there was no evidence that any portion of the P(lacW) element remained in either *mor* or *mor*105.

**Isolation of cDNAs and computer analyses.** To obtain the cDNA corresponding to the 4.5-kb transcript, an early embryonic cDNA library (8) was screened. One positive clone was recovered, and the cDNA insert was subcloned into pBlue-script II SK. DNA, prepared by using a Wizard Miniprep kit (Promega), was sequenced at the sequencing facility of the Life Sciences Institute, Hebrew University, Jerusalem, Israel. Synthetic primers were made to allow complete sequence of both strands. To obtain additional cDNA clones, we screened a random-primed embryonic cDNA library (27) with 5' sequences of the one positive clone and also carried out PCR amplification (with PWO [Boehringer]) on the same library with an oligonucleotide based on the sequence of the non-coding end of Swi3D-2 (5'TCTAACCCGCGCAAGTC' and the 3' reverse primer. Sequences were analyzed by using the National Center for Supercomputer Applications electronic mail server and the Fasta (37), Blast (2), Gap (35), and Pileup (17) programs.

**RNA preparation.** Northern blotting, and determination of the direction of transcription. Developmental Northern blotting of total nucleic acids was performed by grinding frozen samples in a 7 M urea buffer, subjecting them to denaturing gel (12). Developmental Northern blotting of total nucleic acids was performed by grinding frozen samples in a 7 M urea buffer, subjecting them to denaturing gel (12). Total RNA was isolated by homogenizing 200 flies in 1.6 M homogenization buffer (30 mM Tris-Cl [pH 9.0], 10 mM EDTA, 100 mM NaCl, 70 g of sucrose/liter) and 0.4 ml of lysis buffer (0.5 M Tris-Cl [pH 9.0], 0.25 M EDTA, 2.5% sodium dodecyl sulfate [SDS]), incubating at 65°C for 30 min, and, whenever possible, homozygous insertion lines were established. F1 or F2 males were examined for changes in abdominal pigmentation or sternite bristle patterns. The insertion later designated P(lacW)-98B was mapped very close to Sc on the basis of segregation with the original Sc mutation. Mobilization of this element was accomplished by generating dysgenic males, crossing with w females, and recovering w Sc females. Of 47 w Sc chromosomes recovered, 2 were lethal over Df(3R)32B.

**Cloning of the *mor* region and molecular analysis of new excision allelics of *mor***. The P(lacW) element allows cloning of adjacent genomic sequences by plasmid rescue (56). One isolate, pCK5.128A, obtained by EcoRI digestion of flies bearing P(lacW)-98B, was labeled (random priming kit; Bethesda Research Laboratories) and used to screen a StuI3A partial genomic library of Canton-S DNA generated by using a Lambda-FIX kit (Stratagene) and high-molecular-weight genomic DNA (prepared as described in reference 34). Three independent genomic clones were recognized and characterized by restriction mapping and Southern analysis. Smaller genomic fragments were subcloned into pBlue-script II SK (Stratagene).

In the newly obtained excision mutants, *mor* and *mor*105, were subjected to Southern analysis with HindIII or EcoRI as described previously (12). As controls, the transgenesis P(lacW)-98B chromosome and a line thought to be the precise excision thereof were also analyzed. Consistent evidence of changes in both lines was obtained by using the probe CK126 (Fig. 1A). When the original blot was reprobed with pCaSpeR and pBlue-script, there was no evidence that any portion of the P(lacW) element remained in either *mor* or *mor*105.

**Isolation of cDNAs and computer analyses.** To obtain the cDNA corresponding to the 4.5-kb transcript, an early embryonic cDNA library (8) was screened. One positive clone was recovered, and the cDNA insert was subcloned into PBlue-script II SK. DNA, prepared by using a Wizard Miniprep kit (Promega), was sequenced at the sequencing facility of the Life Sciences Institute, Hebrew University, Jerusalem, Israel. Synthetic primers were made to allow complete sequence of both strands. To obtain additional cDNA clones, we screened a random-primed embryonic cDNA library (27) with 5' sequences of the one positive clone and also carried out PCR amplification (with PWO [Boehringer]) on the same library with an oligonucleotide based on the sequence of the non-coding end of Swi3D-2 (5'TCTAACCCGCGCAAGTC' and the 3' reverse primer. Sequences were analyzed by using the National Center for Supercomputer Applications electronic mail server and the Fasta (37), Blast (2), Gap (35), and Pileup (17) programs.

**RNA preparation.** Northern blotting, and determination of the direction of transcription. Developmental Northern blotting of total nucleic acids was performed by grinding frozen samples in a 7 M urea buffer, subjecting them to phenol-chloroform extractions and ethanol precipitation, and then applying approximately 12 µg of nucleic acid from each time point to a formaldehyde-morpholinepropanesulfonic acid (MOPS) denaturing gel (2).

To determine the direction of transcription of the 4.5-kb transcript, single-stranded RNA probes were generated from subclones of the 1.3-kb EcoRI fragment to the left of P(lacW)-98B insertion, placed in both orientations into pBlue-script II SK. These constructs were used to probe the total nucleic acid blots.

**Southern blotting of DNA derived from fruit flies mutant in *mor***. DNA was isolated by homogenizing 200 flies in 1.6 M homogenization buffer (30 mM Tris-Cl [pH 9.0], 10 mM EDTA, 100 mM NaCl, 70 g of sucrose/liter) and 0.4 ml of lysis buffer (0.5 M Tris-Cl [pH 9.0], 0.25 M EDTA, 2.5% sodium dodecyl sulfate [SDS]), incubating at 65°C for 30 min, and, after addition of 0.5 µl of 8 M potassium acetate, incubating at 37°C for 10 min at 0°C. Following centrifugation, 10 µg of ethanol-precipitated DNA was used per lane. Southern blots were prehybridized at 65°C in 6x SSC (1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate) containing 1% N-lauroylsarcosine, 50 µg of 32P-herring sperm DNA (specific activity of 50 Ci/mmol) and, following addition of the probe, hybridized overnight. The washes reached a stringency of 0.1x SSC-0.5% N-lauroylsarcosine. The Swi3D probe, encompassing 3.6 kb of Swi3D cDNA (excluding the 5'-most 180 bp of Swi3D-1), was labeled by using a random primer labeling kit (Biological Induction Laboratories). For PCR analysis of homogenous embryos, 3- to 12-h embryos laid by flies carrying *mor* alleles over a TM3-flac au-2 balancer were stained with 5-bromo-4-chloro-3-indoly1-β-D-galactopyranoside (X-Gal) (21). DNA was amplified by using a RedHot Taq polymerase (Advanced Biotechnologies), and the amplified band was isolated for sequencing by using a QIAquick gel extraction kit (Qiagen).

**Element transformation and rescue of the *mor* phenotype.** A genomic Saff fragment approximately 11.8 kb in length (Fig. 1E) was cloned into the Xhol site of the pCS(MasR-4) transformation vector (20). This fragment includes approximately 3 kb of flanking sequence at both the 5' and 3' ends of He99B. Isolates with the fragment inserted in both orientations were recovered and designated pP[11.8A] and pP[11.8B]. The 4.5-kb mRNA is transcribed in the opposite direction relative to the CaSpeR mini-white gene in the pP[11.8A] construct.

**Antibody preparation, affinity purification, and Western blot analyses.** Antibodies were generated against MOR by inserting a 0.9-kb BamHI-EcoRI fragment into the pGEX1 expression vector (Pharmacia LKB Biotechnology Inc.), harvesting the immunogen as described previously (22), and inoculating rabbits with the immunogen in combination with Freund's adjuvant (Sigma). The antibody was affinity purified after being allowed to bind to immunoblots containing the MOR fusion protein as described in reference 25.

**For Western analysis, tissues were homogenized in a solution containing 50 mM Tris-Cl (pH 7.4), 25% glycerol, 6% β-mercaptoethanol, 4% SDS, 1 mM EDTA, protease inhibitors (1 µg of leupeptin/ml, 3 µg of aprotinin/ml, 0.06 µg of antipain/ml, 1 mM phenylmethylsulfonyl fluoride, and a 1:100 dilution of...**
protease inhibitor cocktail P2714 (all from Sigma). The homogenates were boiled for 5 min, and the proteins in the supernatant were separated by SDS-polyacrylamide gel electrophoresis (PAGE) on 7.5% gels. The gels were blotted onto nitrocellulose (Hybond-C; Amersham) and washed previously (22). Protein A-Sepharose beads (Pharmacia) with dimethylpimelimidate (25) were further purified by heparin-agarose chromatography by standard procedures (4). The antibodies generated in this way recognize only one band of about 190 kDa when used in Western analysis of an embryo extract. Next, 15 μl of a BRM-containing embryonic nuclear fraction (see below) was added to 10 μl of beads and incubated for 2 h at 4°C in a total volume of 90 μl of HEMG (25 mM HEPES-KOH [pH 7.6], 0.1 mM EDTA, 12.5 mM MgCl2, 10% glycerol, 1.5 mM diithiothreitol, 1 mM sodium metabisulfide, 0.2 mM AEBSF, 2 mg of leupeptin/ml, and 0.7 mg of pepstatin/ml) containing 0.4 M KCl and 0.1% Triton X-100. After the incubation, the beads were washed once with a 100-fold excess volume of HEMG-0.4 M KCl-0.01% NP-40, resuspended in SDS sample buffer, and analyzed by immunoblotting with antibodies directed against either BRM or MOR.

The BRM-containing fraction was obtained by preparing nuclear extracts from 0- to 6-h-old Drosophila embryos as previously described (22). About 400 μg of protein was further purified by heparin-agarose chromatography by standard procedures (4). The eluate of the heparin-agarose column was fractionated on an 800-ml Sephacryl S-300 gel filtration column equilibrated with HEMG–0.1 M NaCl (TBS). The preimmune or anti-MOR antiserum was applied at a 1:300 dilution in TBS overnight at 4°C. Following washes in TBS and TBS–0.05% Triton X-100 and a 1-h incubation in TBS with 5% normal goat serum (Biological Industries), horseradish peroxidase-conjugated goat anti-rabbit antibodies (Jackson) were applied for 2 h at room temperature at a 1:5,000 dilution. After washes were performed as described above, the immunoreactive bands were detected using enhanced chemiluminescence (ECL; Amersham).

Immunohistochemistry and in situ hybridization. Immunohistochemistry was carried out as described previously (22). In situ hybridizations were carried out by the method of Tautz and Pfeifle (46) with digoxigenin-labeled probes (Boehringer). An approximately 900-bp BamHI-EcoRI fragment extending from nucleotides 319 to 1234 of Swd3D1 was inserted into pbScript II KS to allow synthesis of RNA probes by transcription from both the T7 and T3 promoters. Following color development, the embryos were mounted in JB4 medium (Poly-sciences), viewed under Nomarski optics with a Zeiss Axioskop microscope, and photographed with a T-MAX 100 film (Kodak).

Coimmunoprecipitation experiments. For coimmunoprecipitations, preimmune serum or antibodies to either MOR or BRM were couple to protein A-Sepharose beads (Pharmacia) with dimethylpimelimidate (25). The anti-BRM antibodies were obtained by immunizing rabbits with a peptide corresponding to amino acids 1617 to 1632 of BRM, coupled to keyhole limpet hemocyanin, by the use of standard procedures (25). The antibodies generated in this way recognize only one band of about 190 kDa when used in Western analysis of an embryo extract. Next, 15 μl of a BRM-containing embryonic nuclear fraction (see below) was added to 10 μl of beads and incubated for 2 h at 4°C in a total volume of 90 μl of HEMG (25 mM HEPES-KOH [pH 7.6], 0.1 mM EDTA, 12.5 mM MgCl2, 10% glycerol, 1.5 mM diithiothreitol, 1 mM sodium metabisulfide, 0.2 mM AEBSF, 2 mg of leupeptin/ml, and 0.7 mg of pepstatin/ml) containing 0.4 M KCl and 0.1% Triton X-100. After the incubation, the beads were washed once with a 100-fold excess volume of HEMG-0.4 M KCl-0.01% NP-40, resuspended in SDS sample buffer, and analyzed by immunoblotting with antibodies directed against either BRM or MOR.

The BRM-containing fraction was obtained by preparing nuclear extracts from 0- to 6-h-old Drosophila embryos as previously described (22). About 400 μg of protein was further purified by heparin-agarose chromatography by standard procedures (4). The eluate of the heparin-agarose column was fractionated on an 800-ml Sephacryl S-300 gel filtration column equilibrated with HEMG–0.1 M NaCl (TBS). The preimmune or anti-MOR antiserum was applied at a 1:300 dilution in TBS overnight at 4°C. Following washes in TBS and TBS–0.05% Triton X-100 and a 1-h incubation in TBS with 5% normal goat serum (Biological Industries), horseradish peroxidase-conjugated goat anti-rabbit antibodies (Jackson) were applied for 2 h at room temperature at a 1:5,000 dilution. After washes were performed as described above, the immunoreactive bands were detected using enhanced chemiluminescence (ECL; Amersham).

Nucleotide sequence accession number. The GenBank accession number for the mor cDNA clones isolated in this study is AF103323.
SWI3D is most similar to the other proteins (especially BAF170) in region I, which is rich in prolines as well as hydrophobic and aromatic amino acids, leading to the suggestion that it may be hidden within the SWI-SNF complex (54). Region II is a tryptophan-rich domain which has been termed the SANT domain because of its presence in four proteins (SWI3, ADA2, N-CoR, and TFIIB) that participate in basal or activated transcription (1). Region III contains a leucine zipper oligomerization motif, suggesting that SWI3D may be able to bind to itself or another leucine zipper-containing protein. In addition to these conserved domains, the carboxy terminus of SWI3D is like those of BAF170, BAF155, and SRG3, very proline rich, but it is more glutamine rich than the corresponding termini of these proteins.

To isolate further-5' regions of the Swi3D transcript, a random-primed embryonic cDNA library was probed. In this screening, an alternatively spliced cDNA, Swi3D-2 (Fig. 3C), was isolated. Swi3D-2 has a candidate initiator methionine that is preceded by a stop codon. Because of the presence of a 91-bp intron in the Swi3D-2 cDNA, it is missing the sequences which encode the first 19 amino acids of SWI3D-1 and it has a different amino-terminal sequence. Unlike that of SWI3D-1, the amino terminus of SWI3D-2 is very similar to those of BAF155 and BAF170 and a little less similar to that of SRG3 (Fig. 3C).

Analysis of DNA derived from mor mutants with Swi3D probes. To ascribe mor function to either 89B-Helicase or Swi3D, we carried out Southern analyses of DNA extracted from heterozygous flies carrying mor alleles 1 through 6 over the same balancer chromosome. While no differences in the pattern of restriction fragments recognized by the 89B-Helicase probe were observed (data not shown), the Swi3D probe recognized one additional band in DNA extracted from flies heterozygous for the mor allele and digested with either EcoRI (Fig. 4A, left panel), EcoRI plus HincII (Fig. 4A, right panel), or HincII plus XbaI (data not shown). In comparison with those of the other mor alleles, the intensity of the 2.3-kb EcoRI-generated band in mor was reduced to the level of the same band in DNA derived from flies heterozygous for Df(3R)mor, in which the mor locus is completely removed (7). In addition, a new, smaller, cross-hybridizing band appeared. This indicated that the 2.3-kb genomic EcoRI fragment that contains sequences of the Swi3D gene was disrupted in the mor allele.

We reasoned that the apparent reduction in size of the 2.3-kb genomic EcoRI fragment in DNA derived from heterozygous mor flies could be due to an internal deletion. To localize this deletion, DNA from homozygous mor embryos was subjected to PCR amplification with nested oligonucleotides that bracket this region. A 1.7-kb amplicon that was about 300 bp smaller than the equivalent genomic fragment amplified from wild-type DNA was obtained (Fig. 4B). Sequencing of the amplicon derived from mor embryos revealed that it was missing 541 nucleotides of the Swi3D-1 cDNA sequence (nucleotides 2431 to 2970) and contained an insertion of 233 bp of irrelevant DNA that did not match any known sequence. Since there are no introns in this area, these alterations caused the mor genomic EcoRI fragment to be 308 bp smaller than that of wild-type DNA. Thus, the mutation in mor constitutes a deletion of the leucine zipper motif of Swi3D (which begins at nucleotide 2790) and of the carboxy proline- and glutamine-rich sequences that are lost due to premature closure of the translational open reading frame. This strongly suggests that Swi3D is encoded by mor and indicates that the leucine zipper domain and the carboxy-terminal sequences of Swi3D are functionally significant in vivo.
Rescue of the *mor* lethal phenotype with a *Swi3D* transgene.

A large *Sal*I fragment, approximately 11.8 kb, that encompasses all of the genomic region known to correspond to the *Swi3D* transcript (Fig. 1E) was cloned into the P transformation vector pP{CaSpeR-4}. This fragment extends into the 5’ end of the transcribed region of 89B-Helicase but does not include most of the coding sequence of that gene; specifically, the essential ATPase domain (3) is not included. The resulting transformation construct, pP*{mor11.8}* was injected into *y*1*w*1118 embryos. Two transformed lines that carry the

FIG. 3. Sequence of *SWI3D* protein and comparison to related proteins. (A) The amino acid sequence encoded by *Swi3D*-1. The regions that, with small changes, correspond to regions I to III in reference 54 are shown in boldface. The extents of the deletions in the constructs generated for the GST fusion protein interaction assay (Fig. 8) are indicated by underlining; MOR*D*SANT is missing the residues indicated by double underlining, MOR*D*NcoI lacks residues indicated with a single straight or wavy underline, and MOR*D*LEU lacks only the residues with a wavy underline. (B) Alignment of regions I to III of *SWI3D* with the same domains of *BAF170*, *BAF155*, *SRG3*, and *SWI3*. The numbers indicate the positions of the last amino acids in the regions. (C) Alignment of the sequence encoded by *Swi3D*-2 with the amino-terminal sequences of *BAF170*, *BAF155*, and *SRG3*. A stop codon is found 30 nucleotides upstream of the candidate initiator methionine. The next amino acid in the protein encoded by *Swi3D*-2 is tyrosine (Y, shown in position 12 of the sequence in panel A). In panels B and C, amino acids that are identical or similar in all the polypeptide sequences are shaded in black.
amplified fragment of (because of the presence of two introns of 62 and 64 bp). The actual size of the mor
tested over the deletion Df(3R)mor
P{mor
wt} or side in kilobases. (B) PCR amplification of genomic DNA from a single wild-type
rescued (in the cases of mor alleles, including mor
which was generated in the same genetic background as mor
. In addition, the intensity of the 2.3-kb band in DNA derived from heterozygous mor
flies is about 1.7 kb. Molecular size marker posi-
tions are indicated at the left.

P(mor
11.8) transposon on the second chromosome and are homozygous viable were established.

One copy of the P(mor
11.8) transgene was able to rescue all heteroallelic mor
, mor
, mor
, and mor
combinations tested (Table 1). While in the absence of P(mor
11.8) these combinations behaved as complete lethals, in the presence of the transgene they all yielded fertile progeny of the rescued class with a frequency that did not deviate significantly from that expected assuming complete rescue (χ² test, P > 0.05). Identical results were obtained when the rescue of mor
was tested over the deletion Df(3R)mor
. Given the complete rescue observed for the heteroallelic combinations, the observations that homozygous combinations of these alleles were not rescued (in the cases of mor
 and mor
) or showed reduced viability and/or fertility (mor
 and mor
) is almost certainly due to the accretion of other deleterious mutations on these chromosomes. Despite this problem, a homozygous stock of P(mor
11.8); mor
 flies has been established.

The lethal P excision alleles mor
 and mor
 exhibited complete rescue in combination with mor
 but only partial rescue

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Viability</th>
<th>Fertility</th>
<th>Phenotype</th>
</tr>
</thead>
</table>
| P(mor
11.8)/+; mor
 | +         | +         | +         |
| P(mor
11.8)/+; mor
 | +         | +         | +         |
| P(mor
11.8)/+; mor
 | +         | +         | +         |
| P(mor
11.8)/+; mor
 | +         | ND         | +         |
| P(mor
11.8)/+; mor
/Df(3R)mor
 | +         | +         | +         |
| P(mor
11.8)/+; mor
 | +         | +         | +         |
| P(mor
11.8)/+; mor
 | +         | +         | +         |
| P(mor
11.8)/+; mor
/Df(3R)mor
 | +         | A6, wing | +         |

in combination with each other (Table 1). P(mor
11.8); mor
 mor
 adults did survive, but at a statistically significantly lower frequency (P < 0.005 and P < 0.025 in two different crosses). Survivors exhibited reduced fertility and had a smaller wing size. Males exhibited a weak A6 sternite bristle phenotype, similar to that of the original P(lacW)89B insertion. Rescue of mor
 over Df(3R)mor
 gave very similar results (Table 1), while P(mor
7.11.8); mor
 and P(mor
11.8); mor
 flies displayed more severe reductions in viability and fertility. Nonetheless, a homozygous P(mor
11.8); mor
 fly stock has been established. Partial rescue of the mor
 and mor
 phenotypes by the P(mor
11.8) transgene constituted a second case in which the genetic behavior of these alleles differed from that of other mor alleles and suggested that their effects are not restricted to the mor gene (see Discussion).

We conclude that the trxG gene mor encodes SWI3D, a Drosophila homolog of proteins known to function as part of the SWI-SNF complex in yeast and mammals. In the descriptions given below, the SWI3D protein is referred to as the MOR protein. To compare the distribution of MOR with that of BRM, which is also a trxG gene product, and SNR1, which encodes SWI3D, a

![FIG. 5. Visualization of MOR by Western blot analysis of proteins extracted from embryos (E) and adult ovaries (O) and of in vitro-synthesized MOR protein (TNT) with affinity-purified anti-MOR antibodies. The anti-MOR antiserum allowed visualization of a 170-kDa protein made by in vitro transcription and translation of the mor(Swiss3D) cDNA and an endogenous polypeptide of the same size in embryo and ovary extracts (arrow). These bands are not observed in identical Western blots treated with the preimmune serum (left panel). The smaller polypeptide seen in these extracts is likely to represent a degradation product (see text). The positions of molecular size markers are indicated at the right.](http://mcb.asm.org/)
Antibodies against MOR recognize a 170-kDa nuclear protein in embryos. Polyclonal antibodies against a bacterial fusion protein containing amino acids 105 to 411 from the relatively nonconserved amino-terminal domain of MOR upstream of region I were raised in two rabbits. Both of the anti-MOR antisera, but neither of their preimmune controls, recognized a 170-kDa polypeptide when used in Western analysis of proteins extracted from embryos and adult ovaries (data not shown). Because both antisera also recognized additional polypeptides, one of the two anti-MOR antisera was affinity purified against the original immunogen as described in Materials and Methods. When used in Western analysis as described above, the affinity-purified immune serum specifically recognized a precedent 170-kDa band (Fig. 5, right panel) that was not seen in blots probed with the preimmune serum (Fig. 5, left panel).

The endogenous protein is of the same molecular weight as the MOR protein whose synthesis is directed in vitro by Swi3D-1, suggesting that the embryonic mor cDNA clone that we have isolated is complete or nearly so. The molecular mass of 170 kDa was larger than anticipated for MOR, but its human homologs, BAF155 and BAF170, also exhibited slower electrophoretic mobilities than predicted (54). An additional, faint band of about 100-kDa seen in the embryonic and ovarian extracts likely represented a degradation product of the 170-kDa polypeptide because it, as well as the 170-kDa band, was absent from extracts of late-stage homozygous mor embryos selected from among their blue (i.e., heterozygous) siblings (data not shown). In these embryos, the predicted truncated protein was also not seen, probably because of its instability when it cannot be incorporated into a multiprotein complex (see below).

When the affinity-purified anti-MOR antibodies were used to examine the localization of MOR during embryogenesis by immunohistochemistry of whole-mount embryos, a tissue distribution exactly identical to that of mor transcripts was observed. Both the transcripts seen by in situ hybridization (Fig. 6G to K) and the protein visualized with the affinity-purified antibody (Fig. 6A to E) are ubiquitous early in development and highly expressed in the central nervous system and gut of older embryos. Using these antibodies, the subcellular localization of MOR was determined. MOR was present in all of the somatic nuclei of syncytial and cellularizing blastoderm-stage embryos (compare Fig. 6B with Fig. 6A, which was stained with affinity-purified preimmune serum) but not in the posterior pole cells (data not shown). At germ band lengthening, higher levels of MOR were seen in the developing gut (the invaginating endoderm of the posterior midgut and the stomodeum) and the ventral nerve cord (Fig. 6C). In the latter tissue, the nuclear localization of MOR was still apparent. Upon germ band retraction, MOR was preferentially enriched in the mid- and hindguts and in the ventral nerve cord (Fig. 6E; compare with control in Fig. 6D) and the brain (data not shown). At this stage, no subcellular compartmentalization could be discerned.

We examined the level of MOR immunoreactivity in embryos homozygous for Df(3R)mor. Homozygous embryos were identified at the germ-band-extended stage, when the ftz-lacZ gene of the nonhomozygous siblings is maximally expressed and when, presumably, the effects of a possible maternal con-

FIG. 6. mor transcripts and MOR protein, ubiquitously distributed during early development, are enriched in the midgut, hindgut, and CNS of the germ-band-retracted embryo. (B, C, E, G, I, and J) In situ and immunohistochemical visualization of the distribution of mor transcripts and MOR protein at stage 4 (B and G), stage 10 (C and I), and stage 14 (E and J). (F) A Df(3R)mor embryos at the same stage as the embryo shown in panel C. (A, D, H, and K) Control embryos stained with affinity-purified preimmune serum (A and D) or treated with a digoxigenin-labeled sense strand probe (H and K) at stage 4 (A and H) and stage 14 (D and K). Note the nonspecific staining of the amnioserosa in panels D and E. Anterior is to the left. Staging is according to reference 26.
The interaction between molecules of MOR was verified independently in the yeast two-hybrid assay. A fragment of MOR identical to that present in GST-MOR was fused both to the LexA DNA-binding domain of the LEXA202 vector (40) and to the activation domain of the pJG4-5 plasmid (23). Simultaneous transformation of S. cerevisiae by both plasmids activated the lacZ of a reporter gene containing LexA binding sites, as evidenced by the blue color of colonies on X-Gal plates, while expression of either fusion protein alone did not induce blue-colony formation (not shown).

The above observations indicate that MOR is able to self-associate and that the amino-terminal sequences of MOR cannot mediate binding between two molecules of MOR. To further localize the sequences in MOR that are required for this interaction, we labeled deleted forms of the MOR protein (Fig. 3A and 8A): MOR\(\Delta\)NcoI, which lacks the entire highly conserved leucine zipper domain and extensive flanking sequence; MORA\(\Delta\)SANT, which is missing 38 of 90 amino acids in the leucine zipper motif and the proline- and glutamine-rich carboxy-terminal region; and MOR\(\Delta\)SANT, from which half (56 amino acids) of the SANT domain, as well as 37 somewhat-less-conserved residues N terminal to it, has been deleted. The MOR derivatives were tested for retention by the immobilized GST-MOR fusion protein. Removal of half of the SANT domain in MOR\(\Delta\)SANT did not appear to affect the ability of MOR to homo-oligomerize (14-fold greater retention than binding of full-length MOR to GST alone) (Fig. 8B, lane 6). (Note that slightly less radiolabeled MOR\(\Delta\)SANT was loaded onto the GST-MOR fusion protein [Fig. 8B, lane 11], thus largely accounting for the smaller amount retained.) However, self-association was severely compromised by removal of the extended leucine zipper domain in MOR\(\Delta\)NcoI (only fourfold greater retention in lane 4 than in lane 1). Reproduction of part of the leucine zipper motif in the MORA\(\Delta\)LEU construct appeared to restore some of the binding activity (sevenfold greater retention) (lane 5). These data indicate that MOR is capable of forming homooligomers and that region III, the leucine zipper motif, is likely to contribute to this interaction.

**MOR binds to BRM.** MOR was tested for its ability to interact with BRM, with which it is associated in embryonic nuclear extracts. In these experiments, we focused on domain II of BRM because deletion of this region causes a decrease in the size of the BRM complex, presumably due to the loss of one or several subunits (16), and because yeast two-hybrid analysis revealed an interaction between this domain of SWI2-SNF2 and the SWI3 subunit of the yeast complex (47, 48). While domain II of BRM consists of residues 549 to 610, the two GST fusion proteins that were generated for the interaction assay were more extensive and included amino acids 230 to 736 or 524 to 736. At 200 mM NaCl, labeled full-length MOR was retained on the immobilized GST-BRM fusion protein containing residues 230 to 736 approximately as well as it was retained by immobilized GST-MOR (12- and 13-fold greater retention than of full-length MOR to GST alone) (Fig. 8C, lanes 1 and 3). In contrast, binding of MOR to beads bearing the same amount of a GST-BRM fragment containing only amino acids 524 to 736 was much less efficient (sevenfold greater retention) (lane 6). Thus, MOR is able to interact with BRM and this association can be mediated by 507 amino acids in BRM that include domain II.

To examine the role of different protein domains of MOR in binding to BRM, we tested the ability of the MOR deletion constructs to be retained by the BRM fusion proteins. MORA\(\Delta\)NcoI was efficiently retained by GST-BRM 230–736 (15-fold greater retention in lane 4 than in lane 2), implying that the association of MOR with itself or another leucine
FIG. 8. Protein interactions of MOR assayed by the GST fusion protein interaction assay. (A) Domains of the MOR protein, with lengths shown below in amino acids. Shown are domains included in GST-MOR constructs and the deleted derivatives of MOR that were radiolabeled and tested for their ability to bind to immobilized fusion proteins. (B) MOR-MOR interactions. Full-length MOR did not bind to GST residues alone (lane 1) or to the amino-terminal sequences of MOR in GST-MOR-NH2 (lane 2). In contrast, there was efficient retention by GST-MOR (lane 3), even in the presence of ethidium bromide (lane 7). Lanes 4 to 6 show binding of different MOR deletion derivatives to GST-MOR. Lanes 8 to 11 indicate the relative amounts of radiolabeled MOR and MOR derivatives that were incubated with the GST fusion proteins. (C) MOR-BRM interactions. Full-length MOR bound to the large BRM fusion protein (lane 3) about as well as it did to GST-MOR (lane 1). Lanes 3 to 5 compare retention of the different MOR deletion derivatives to the large BRM fusion protein, and lanes 6 to 8 compare their binding to the small BRM fusion protein. Lane 2 shows binding of full-length MOR to GST alone. Lanes 9 to 11 indicate the relative amounts of the radiolabeled proteins that were used. The positions of molecular mass markers are shown at the left (in kilodaltons).
zipper-containing protein is not necessary for its binding to BRM. This is not the case for MOR\_SANT, whose binding to an equivalent amount of the large BRM fusion protein was significantly reduced relative to the binding of full-length MOR (only fourfold-greater retention in lane 5 than in the control). While MOR\_SANT was retained, albeit poorly, by the smaller BRM fusion protein (sixfold-greater retention in lane 7 than in lane 2), the level of retention of MOR\_SANT fell almost to that of the negative control (twofold-greater retention than binding of the full-length protein to beads carrying GST alone) (compare lanes 8 and 2). These results suggest that the SANT domain of MOR may play a role in the association of MOR with domain II and adjacent residues of BRM.

**DISCUSSION**

The fruit fly BAF170/BAF155/SWI3 homolog is a member of the trxG proteins. We have isolated a *Drosophila* homolog of the yeast SWI3 gene and the human BAF170 and BAF155 genes and demonstrated that it is encoded by the previously known trxG locus *mor*. Its identification as *mor* was achieved by Southern analyses of DNA derived from flies with mutations in *mor*, by characterization of a genomic Swi3D fragment derived from homozygous *mor* embryos, and by rescue of the *mor* phenotype. The origin of *mor* by \-ray mutagenesis (29) is consistent with our observation that it encodes an altered form of *mor* in which 541 bp have been deleted and a 233-bp insertion of foreign DNA has occurred, leading to loss of the leucine zipper motif as well as the carboxy-terminal proline- and glutamine-rich sequences.

Genomic DNA encoding the Swi3D gene is able to completely rescue the lethal phenotype of *mor* alleles 1, 2, 5, and 6. In contrast, introduction of the entire neighboring 89B-Helicase cDNA into the background of the *mor* allele in combination with *mor* is completely inefficacious in rescuing the heteroallelic lethal phenotype (55). Thus, the 5' portion of the 89B-Helicase gene included within the *P(mor)11.8* construct is not mediating the observed rescue. On the other hand, the residual phenotype observed in flies carrying the *mor* and *mor* alleles after introduction of *P(mor)11.8* is likely to be due to the effect of these mutations on the 89B-Helicase gene rather than failure of the transgene to completely compensate for the *mor* deficiency. We interpret this to be the case because the 89B-Helicase transgene appears to be able to rescue the bristle phenotype that is associated with *P(lacW)89B* (55). It will be interesting to test whether the introduction of both transgenes results in the complete rescue of the *mor9* *mor10* phenotypes.

**MOR is a component of the *Drosophila* counterpart of the yeast SWI-SNF complex.** We have observed that the *Drosophila* BAF170/BAF155/SWI3 homolog, encoded by *mor*, is physically associated with BRM in embryonic nuclear extracts. The presence of an identical protein, named BAP155, in a highly purified 2-MDa BRM complex isolated from *Drosophila* embryos was very recently reported by Papoulas et al. (36). Significantly, analysis of the eight subunits of the BRM complex revealed that MOR/BAP155 is the only component, other than BRM and the previously identified SNR1 (14), that is encoded by a trxG gene. Two additional trxG proteins, ASH1 and ASH2, were found to be present in distinct high-molecular-mass complexes.

The identification of *mor* as a gene encoding a component of the *Drosophila* BRM-containing complex provides a biochemical basis for the close functional relationship between *mor* and *brm*, both strong and well-characterized trxG member. Indeed, the phenotypes resulting from mutations in each of these two genes exhibit many similarities. For example, alleles of both *mor* and *brm* were repeatedly isolated in genetic screens for dosage-dependent modifiers of dominant mutations in *Pc* (29); mutations in either gene affect transcription of multiple homoeotic genes and the segmentation gene, *engrailed*; both of them are required for oogenesis; and both may be involved in cell viability of imaginal disc cells but not abdominal histoblasts (6, 7, 16, 44). More recently, *mor* was the only trxG gene found to interact with a dominant-negative *brm* transgene (36). Further analysis will be required to clarify the relationships of the trxG genes that are not components of the BRM complex to MOR and BRM.

**Comparison of mor gene product distribution with those of brm and Snr1.** The expression pattern of *mor* overlaps with those of *brm* and *Snr1* but is more widespread. The presence of *mor* transcripts in unfertilized eggs, as determined by Northern analysis, suggests that there is a maternal contribution of the *mor* gene product, as has been reported for *brm* and *Snr1* (6, 14). In addition, *mor*, like *brm* and *Snr1*, is most highly expressed in young embryos up to 8 h of age (14, 15). Unlike those of *brm* and *Snr1*, *mor* transcripts are also present in adult males. Although *brm* transcripts were not detected in adult males, low levels of BRM protein have been reported (16).

During early embryonic development, *mor* transcripts and the nucleus-localized MOR protein exhibit a ubiquitous distribution like that of BRM and SNR1 (14, 16). After germ band retraction, they are observed at high levels in the central nervous system (CNS) and in the mid- and hindgut. This contrasts with *Snr1*, which is almost exclusively found in the ventral nerve cord and brain at the end of embryogenesis (14), and BRM, which is ubiquitously expressed and only somewhat localized to the CNS (16). Expression of *mor* transcripts and protein in the endodermal primordium is consistent with the midgut abnormalities described in *mor* mutant embryos (7) and suggests that MOR is functional in this tissue. It will be interesting to determine whether MOR is more stable in the cytoplasm, since in *Df(3R)mor* embryos what we assume to be a small amount of residual maternally derived MOR protein appears to be preferentially retained in the midgut and stomodeum, tissues in which nuclear enrichment of MOR has not been observed.

**Protein interactions of MOR.** The protein-protein interactions that stabilize the SWI-SNF complex are not well understood. Some of the direct associations that have been reported are binding of TFG3/TAF30 and SNF5 (10) and an interaction between SNF11 and SNF2 (47). Because of the presence of a putative leucine zipper motif in MOR, we examined the ability of MOR to self-associate, using a GST fusion protein interaction assay and the yeast two-hybrid system. Our data indicate that MOR is able to oligomerize in vitro and in vivo in the yeast two-hybrid system. In addition to demonstrating an in vivo interaction between two molecules of MOR, our results indicated that a MOR derivative containing most of domain I, all of domains II and III, and most of the proline- and glutamine-rich tail cannot activate transcription when artificially tethered to DNA. This could be due to the absence of essential MOR sequences or to the inability of the fruit fly protein to nucleate assembly of the entire yeast complex. By comparison, SWI2-SNF2, SNF5, and SNF6 all function as activators when targeted to a promoter as LexA fusions (32, 33).

Neither region I nor the SANT domain has to be complete for self-binding of MOR to occur. Since oligomerization is sensitive to the extent of removal of the leucine zipper domain, our results strongly suggest that the leucine zipper motif of MOR contributes to the ability of this protein to self-associate
in vitro, but they do not eliminate the possibility that the carboxy-terminal region is involved.

The demonstration that MOR is able to self-associate raises the possibility that it is present in two copies in each complex, similar to BAF170 and BAF155, which are both present in each human complex (53, 54). These results support a dimer-like model for the structure of the SWI-SNF complex, with duplication of some or all subunits. Such a model has been proposed previously because the overall molecular mass of the complex is much greater than the sum of its individual components (54). It is also possible, however, that in vivo, the leucine zipper motif of MOR is involved in an association between MOR and a different leucine zipper-containing protein. In either case, the embryonic-lethal phenotype resulting from deletion of the leucine zipper and carboxy terminus in the polypeptide encoded by the mor allele suggests that these domains are functionally required in vivo. Robust assembly into the BRM-containing complex via interactions involving the leucine zipper motif may affect the stability of the MOR protein, since we are unable to visualize the truncated protein domains are functionally required in vivo. Robust assembly script.

We tested whether MOR, which is complexed with BRM in embryonic nuclear extracts, is able to interact with this protein in vitro. The data indicate that such an interaction can occur and that it involves domain II of BRM, as well as adjacent residues on the amino-terminal side of this domain. The motif in MOR which may mediate the interaction with BRM is the SANT domain. The possible role of the SANT domain is suggested by the significant reduction in the binding of MOR to BRM when 56 amino acids of this domain are deleted, but a role for an additional 37 non-SANT domain residues that were also removed cannot be excluded. Unlike the related DNA-binding domain in the MYB family of proteins, the SANT domain in BAF170 was not shown to have detectable DNA-binding activity in gel shift assays (54), and its function is unknown. These findings, for the first time, ascribe a possible role for the SANT domain in protein-protein interactions.

ACKNOWLEDGMENTS

We thank Daniel Jay, in whose laboratory portions of this work were carried out; James Kennison, who provided mora stocks; Yossi Markson for limitless patience in preparing the figures; Simon Greenberg, who assisted in DNA analysis; and Benny Shilo for reading the manuscript.

M.A.C. was supported by a grant from the National Science Foundation; N.B.Z. was supported by grants from the Israel Cancer Research Fund and the Israel Academy of Science. M.A.C. and C.M. contributed equally to this work.

REFERENCES


